ArticleJournal of pharmaceutical health care and sciences2026
Comparison of an HPLC-UV system (LM1010) and UPLC-MS/MS for plasma voriconazole measurement in routine clinical practice.
Article in Journal of pharmaceutical health care and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to evaluate the clinical utility of the LM1010 high-performance liquid chromatography with ultraviolet-visible detection instrument for measuring plasma concentrations of voriconazole (VRCZ) under routine clinical conditions, including in patients with diverse clinical backgrounds.
methodsIn total, 213 samples were collected from two hospitals (groups A and B). The plasma samples were analyzed using LM1010 and ultra performance liquid chromatography (UPLC)-tandem mass spectrometry (MS/MS). Laboratory test values and information on concomitant medications were collected from electronic medical records.
resultsIn total, 66 samples from group A and 135 samples from group B were included in the analysis. Passing–Bablok regression analysis showed that in group A (n = 66), the slope was 0.972 (95% confidence interval [CI], 0.929–1.000) and the intercept −0.024 (95% CI, −0.100–0.056), indicating no significant proportional or constant bias. In group B (n = 135), the slope was 0.956 (95% CI, 0.930–0.975) and the intercept −0.006 (95% CI, −0.053–0.025), indicating a slight proportional bias but no constant bias. The Bland–Altman analysis demonstrated proportional bias in both groups A and B, and the slopes of the regression lines were 0.045 (95% CI, 0.011–0.079) and 0.038 (95% CI, 0.025–0.052), respectively. Interfering peaks were observed in the chromatograms of eight samples in group B, but their effect on the intermethod difference was small. No clinical laboratory test values or concomitant medications were identified as factors affecting the intermethod difference.
conclusionsThe measurement of VRCZ plasma concentration by LM1010 was robust under heterogeneous clinical conditions and was useful for clinical therapeutic drug monitoring of VRCZ.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.